SCHEMBL19669740

SCHEMBL19669740

CN1CCN(C/C=C/C(=O)NC(C)(C)C)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.38
TNIK Q9UKE5 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
BTK Q06187 1/20 0.36
EGFR P00533 4/20 0.35
KDM4E B2RXH2 1/20 0.35
ERBB4 Q15303 2/20 0.34
ERBB2 P04626 1/20 0.34
JAK3 P52333 1/20 0.34
ALDH1A1 P00352 2/20 0.34
JAK2 O60674 1/20 0.34
FLT3 P36888 1/20 0.34
PAOX Q6QHF9 1/20 0.33
HDAC3 O15379 1/20 0.33
HDAC4 P56524 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC7 Q8WUI4 1/20 0.33
HDAC2 Q92769 1/20 0.33
HDAC10 Q969S8 1/20 0.33
HDAC11 Q96DB2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19669738 0.88 SMN1; SMN2 (0.38) LMNASMN1; SMN2EGFRKDM4EALDH1A1
SCHEMBL19912771 0.87 PKM (0.36) LMNASMN1; SMN2EGFRKDM4EALDH1A1
SCHEMBL19912779 0.87 SMN1; SMN2 (0.45) LMNASMN1; SMN2BTKEGFRERBB2
SCHEMBL24637162 0.86 EGFR (0.34) LMNATNIKSMN1; SMN2EGFRALDH1A1
SCHEMBL19442308 0.85 SMN1; SMN2 (0.47) LMNASMN1; SMN2BTKEGFRERBB2
SCHEMBL15601163 0.84 KMT2A (0.36) LMNASMN1; SMN2EGFRKDM4EALDH1A1
SCHEMBL15600836 0.83 SIGMAR1 (0.41) LMNASMN1; SMN2EGFRKDM4EALDH1A1
SCHEMBL14079970 0.83 CHRNB2 (0.40) TNIKBTKEGFRKDM4EERBB4
SCHEMBL15600841 0.83 SMN1; SMN2 (0.53) SMN1; SMN2BTKEGFRKDM4EERBB2
SCHEMBL19669739 0.82 ALDH1A1 (0.35) LMNAEGFRKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9834571-B2 Compounds for inhibiting cell proliferation in EGFR-driven cancers ARIAD PHARMACEUTICALS, INC. (US) 2017-12-05 US disclosed